Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Artelo BiosciencesARTL +2.68%31 Equity-to-Asset is 0.53 as of Mar. 2026, which is 40% below its 10-year median of 0.88. GuruFocus rates ARTL with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 1,417 Biotechnology companies, Artelo Biosciences ranks worse than 65.63% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Artelo Biosciences Equity-to-Asset Related Terms
Artelo Biosciences Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Artelo Biosciences's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ARTL vs REVB, MTNB, ONCO: Equity-to-Asset Comparison
For the Biotechnology subindustry, Artelo Biosciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Artelo Biosciences Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Artelo Biosciences's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Artelo Biosciences's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Artelo Biosciences's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Artelo Biosciences (ARTL) has a Equity-to-Asset of 0.53 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Artelo Biosciences and its competitors. This is 40% below median its historical median of 0.88. According to the industry distribution chart, Artelo Biosciences ranks #930 out of 1417 companies in the Biotechnology industry, placing it in the top 65.6%.
Is Artelo Biosciences' Equity-to-Asset too high?
Artelo Biosciences' current Equity-to-Asset of 0.53 is 40% below median its 10-year median of 0.88. The Biotechnology industry median Equity-to-Asset is 0.68. Artelo Biosciences' value of 0.53 is 22.1% below this industry median. Based on the distribution chart, Artelo Biosciences ranks #930 out of 1417 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Artelo Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Artelo Biosciences' Equity-to-Asset compare to REVB and MTNB?
According to the Biotechnology industry distribution chart, Artelo Biosciences ranks #930 out of 1417 companies for Equity-to-Asset. This places Artelo Biosciences in the lower half of its industry. The industry median Equity-to-Asset is 0.68. Artelo Biosciences' value of 0.53 is 22.1% below this benchmark. While the company's 10-year median is 0.88 vs. the industry median of 0.68, Artelo Biosciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Artelo Biosciences's current Equity-to-Asset of 0.53 is 22.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Artelo Biosciences and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Artelo Biosciences's current Equity-to-Asset is 0.53, which is 40% below median its own 10-year median of 0.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artelo Biosciences stock overvalued right now?
Artelo Biosciences (ARTL) has a current Equity-to-Asset of 0.53. The current Equity-to-Asset is 0.53, which is 40% below median its 10-year median of 0.88 and 22.1% below the Biotechnology industry median of 0.68. Artelo Biosciences' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Artelo Biosciences (ARTL), the current Equity-to-Asset is 0.53 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
31GF Score
Get the complete analysis for ARTL
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARTL has been successfully added to your 
